RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Newsroom

Josephine Mauskopf elected to International Society for Pharmacoeconomics and Outcomes Research board of directors

RESEARCH TRIANGLE PARK, N.C. — Josephine Mauskopf, Ph.D., vice president of Health Economics at RTI Health Solutions, a business unit of RTI International, has been elected to the board of directors of the International Society for Pharmacoeconomics and Outcomes Research. She will serve a two-year term.

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) promotes pharmacoeconomics (health economics) and outcomes research, and connects important information to health care decision makers. ISPOR has more than 13,000 members worldwide in nearly 100 countries.

Mauskopf is a recognized leader in the development and application of state-of-the art research methods, particularly for budget impact analysis.

Last year, Mauskopf received the ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award, honoring her significant contributions to the science of pharmacoeconomics and outcomes research.

Her work has included estimating the cost of illness of viral and fungal infections, psychiatric illness and neurologic diseases, and evaluating the cost-effectiveness and budget impacts of new therapies for these diseases. She has presented her research at numerous national and international symposia, and authored more than 140 peer-reviewed publications.